This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Digging into the recent data from the MAESTRO-NASH phase 3 trial of Madrigal Pharmaceuticals' resmetirom in NASH
Ticker(s): MDGLWho's the expert?
Institution: Texas Liver Institute
- Medical Director and VP of Research and Development at the Texas Liver Institute and Professor of Medicine at the University of Texas Health San Antonio.
- Manages hundreds of patients with NASH.
- Has authored over 400 peer-reviewed publications in medical journals.
Interview GoalThis conversation will focus on discussing the recent phase 3 data released by Madrigal Pharmaceuticals' on resmetirom for nonalcoholic steatohepatitis(NASH) and liver fibrosis.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
